Watch our webinar - Harnessing the benefits of GDUFA 3 commitment letter.

Harnessing the benefits of GDUFA III commitment letter

First Name *

Last Name *

Company *

Designation *

Department *

Email *

Contact Number *

Country *

Country Code

State

I would like expert insights on navigating the ANDA review process and accelerating approvals.

* indicates mandatory fields.
The information you provide on this form will help us deliver relevant updates and marketing by email. We will never share or sell your personal information. You can unsubscribe at any time by simply clicking the 'unsubscribe' link in the footer of our emails, or by replying with a request to be removed from our list. To find out more please read our privacy policy

Watch our informative webinar, in which we have covered the enhancements to the review of abbreviated new drug applications under GDUFA III, including review-cycle changes, meeting types, and additional opportunities for pre-submission engagement and review with the agency.